Novartis Execs Highlight Cosentyx, LCZ696 As Key 2015 Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.
You may also be interested in...
Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class
Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.
Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class
Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.
EU Clears GSK-Novartis And Mylan-Abbott Deals, With Minor Conditions
Meningitis and tetanus-diphtheria vaccines and smoking cessation products will be divested by GSK in Europe, and B-Raf and MEK inhibitors by Novartis, while Mylan will divest four generics in five markets.